Tobias Raphael Overbeck
Overview
Explore the profile of Tobias Raphael Overbeck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
25
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Treatment of non-small cell lung cancer: advances following the introduction of PET-CT and IMRT/VMAT
Muster J, Alt N, Edelmann M, Anczykowski M, Zwerenz C, Schirmer M, et al.
Strahlenther Onkol
. 2025 Mar;
PMID: 40050448
Purpose: In definitive radiotherapy/radiochemotherapy (RT/RCT) for localized non-small cell lung cancer (NSCLC), the introduction of positron-emission tomography (PET)-CT-based staging/RT planning and dynamic RT techniques (intensity-modulated radiotherapy, IMRT/volumetric modulated arc therapy,...
2.
Webendorfer M, Heinzen S, Sibbert C, Lessmann M, Kropf-Sanchen C, Thomas M, et al.
Oncol Res Treat
. 2024 Dec;
48(3):142-147.
PMID: 39626649
No abstract available.
3.
Ziegler D, Cleve C, Ziegler S, Schirmer M, Fischer L, Bohnenberger H, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893074
In this study, we investigated the outcomes and factors influencing treatment efficacy in 93 patients with limited disease small cell lung cancer (LD-SCLC), with a median age of 64 years....
4.
Illini O, Saalfeld F, Christopoulos P, Duruisseaux M, Vikstrom A, Peled N, et al.
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612799
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed...
5.
Kemper M, Soltani Germy P, Acker F, Luan J, Griesinger F, Tufman A, et al.
Oncol Res Treat
. 2024 Apr;
47(6):312-315.
PMID: 38574467
No abstract available.
6.
Acker F, Luan J, Soltani Germy P, Kemper M, Blasi M, Griesinger F, et al.
Oncol Res Treat
. 2024 Mar;
47(6):306-311.
PMID: 38527447
No abstract available.
7.
Alt N, Muster J, Ziegler D, Bendrich S, Donath S, Hille A, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38254817
Identification of the optimal treatment strategy is challenging in elderly with localized non-small cell lung cancer (NSCLC). Concurrent chemotherapy with low-dose cisplatin represents an option for elderly. Outcomes (1) in...
8.
Habermann F, Schmitt D, Failing T, Ziegler D, Fischer J, Fischer L, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201658
The internal organ at risk volume (IRV) concept might improve toxicity profiles in stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC). We studied (1) clinical aspects in...
9.
Overbeck T, Reiffert A, Schmitz K, Rittmeyer A, Korber W, Hugo S, et al.
Cancers (Basel)
. 2023 Jun;
15(11).
PMID: 37296928
(1) Background: The main objectives of our study are (i) to determine the prevalence of () fusions in a routine diagnostic setting in NSCLC (non-small cell lung cancer) and (ii)...
10.
Guhlich M, Maag T, Droge L, El Shafie R, Hille A, Donath S, et al.
Strahlenther Onkol
. 2022 May;
198(12):1072-1081.
PMID: 35552767
Purpose: Superior vena cava syndrome (SVCS) often results from external vessel compression due to tumor growth. Urgent symptom-guided radiotherapy (RT) remains a major treatment approach in histologically proven, rapidly progressive...